Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Maurizio Fava, M.D.

Co-Author

This page shows the publications co-authored by Maurizio Fava and Cristina Cusin.
Connection Strength

5.426
  1. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2017 Jan; 51(1):55-64.
    View in: PubMed
    Score: 0.712
  2. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012 Aug; 169(8):868-9.
    View in: PubMed
    Score: 0.524
  3. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. J Affect Disord. 2020 11 01; 276:660-666.
    View in: PubMed
    Score: 0.228
  4. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604.
    View in: PubMed
    Score: 0.227
  5. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.224
  6. All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. Am J Psychiatry. 2020 02 01; 177(2):173-174.
    View in: PubMed
    Score: 0.220
  7. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.212
  8. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.205
  9. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.201
  10. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord. 2019 01 15; 243:516-524.
    View in: PubMed
    Score: 0.200
  11. Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]. J Affect Disord. 2018 02; 227:198.
    View in: PubMed
    Score: 0.189
  12. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.187
  13. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017 Jan 15; 208:6-14.
    View in: PubMed
    Score: 0.175
  14. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. J Clin Psychiatry. 2016 06; 77(6):e719-25.
    View in: PubMed
    Score: 0.171
  15. A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. Ther Adv Psychopharmacol. 2016 Feb; 6(1):4-12.
    View in: PubMed
    Score: 0.167
  16. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013 Jul; 74(7):e636-41.
    View in: PubMed
    Score: 0.140
  17. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom. 2012; 81(5):312-4.
    View in: PubMed
    Score: 0.131
  18. Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder. Psychol Med. 2014 May; 44(7):1361-7.
    View in: PubMed
    Score: 0.128
  19. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom. 2007; 76(1):40-6.
    View in: PubMed
    Score: 0.089
  20. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry. 2007 Jan; 68(1):52-7.
    View in: PubMed
    Score: 0.089
  21. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005; 5(11):1077-86.
    View in: PubMed
    Score: 0.077
  22. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom. 2005; 74(6):362-5.
    View in: PubMed
    Score: 0.077
  23. Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychol Med. 2020 Nov 20; 1-9.
    View in: PubMed
    Score: 0.058
  24. PET imaging of neurotransmission using direct parametric reconstruction. Neuroimage. 2020 11 01; 221:117154.
    View in: PubMed
    Score: 0.057
  25. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 10 01; 177(10):965-973.
    View in: PubMed
    Score: 0.057
  26. Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study. J Clin Psychiatry. 2020 06 09; 81(4).
    View in: PubMed
    Score: 0.056
  27. Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. Psychol Med. 2020 Mar 06; 1-9.
    View in: PubMed
    Score: 0.055
  28. The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause. Psychoneuroendocrinology. 2020 02; 112:104512.
    View in: PubMed
    Score: 0.054
  29. Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. J Affect Disord. 2020 02 01; 262:118-125.
    View in: PubMed
    Score: 0.054
  30. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.054
  31. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.051
  32. Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomed Laser Surg. 2018 Dec; 36(12):634-646.
    View in: PubMed
    Score: 0.050
  33. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. J Clin Psychiatry. 2018 Jan/Feb; 79(1).
    View in: PubMed
    Score: 0.048
  34. Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. J Psychiatr Res. 2015 Nov; 70:98-105.
    View in: PubMed
    Score: 0.041
  35. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015; 2015:352979.
    View in: PubMed
    Score: 0.040
  36. Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. Hum Brain Mapp. 2015 Sep; 36(9):3472-85.
    View in: PubMed
    Score: 0.040
  37. A computational analysis of flanker interference in depression. Psychol Med. 2015 Aug; 45(11):2333-44.
    View in: PubMed
    Score: 0.039
  38. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9.
    View in: PubMed
    Score: 0.039
  39. Correlates of irritability in college students with depressive symptoms. J Nerv Ment Dis. 2013 Nov; 201(11):953-8.
    View in: PubMed
    Score: 0.036
  40. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry. 2007 Sep 01; 62(5):536-40.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.